Thomas Wierzba to Vaccines, Conjugate
This is a "connection" page, showing publications Thomas Wierzba has written about Vaccines, Conjugate.
Connection Strength
0.672
-
Kim SH, Pezzoli L, Yacouba H, Coulibaly T, Djingarey MH, Perea WA, Wierzba TF. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS One. 2012; 7(1):e29116.
Score: 0.422
-
Wierzba TF, Sanders JW. The global burden of enteric fevers in the age of typhoid-conjugate vaccines. Lancet Infect Dis. 2019 04; 19(4):340-341.
Score: 0.172
-
Jeon HJ, Pak GD, Im J, Owusu-Dabo E, Adu-Sarkodie Y, Gassama Sow A, Bassiahi Soura A, Gasmelseed N, Keddy KH, Bjerregaard-Andersen M, Konings F, Aseffa A, Crump JA, Chon Y, Breiman RF, Park SE, Cruz Espinoza LM, Seo HJ, May J, Meyer CG, Andrews JR, Panzner U, von Kalckreuth V, Wierzba TF, Rakotozandrindrainy R, Dougan G, Levine MM, Hombach J, Kim JH, Clemens JD, Baker S, Marks F. Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease. Clin Infect Dis. 2018 11 28; 67(12):1824-1830.
Score: 0.042
-
Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016 06 03; 34(26):2887-2894.
Score: 0.035